Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.48 |
| ▸ | WNT3A | P56704 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1647594 | 0.80 | KMT2A (0.51) | KMT2ATHRBCTNNB1WNT3AALDH1A1 | |
| Bromide SCHEMBL7770547 | 0.78 | KMT2A (0.53) | KMT2ACTNNB1WNT3AALDH1A1CES2 | |
| Bromide SCHEMBL3890163 | 0.78 | KMT2A (0.49) | KMT2ATHRBSMN1; SMN2NPC1POLB | |
| Bromide SCHEMBL3885379 | 0.78 | KMT2A (0.66) | KMT2ATHRBALDH1A1SMN1; SMN2NPC1 | |
| Bromide SCHEMBL5900356 | 0.77 | KMT2A (0.51) | KMT2ACTNNB1WNT3AALDH1A1CES2 | |
| Bromide SCHEMBL1645919 | 0.76 | KMT2A (0.73) | KMT2ATHRBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2601877 | 0.76 | LMNA (0.53) | KMT2ACTNNB1WNT3AALDH1A1CES2 | |
| Bromide SCHEMBL3843812 | 0.76 | KMT2A (0.54) | KMT2ACTNNB1WNT3AALDH1A1CES2 | |
| Bromide SCHEMBL8081586 | 0.76 | KMT2A (0.54) | KMT2ACTNNB1WNT3AALDH1A1CES2 | |
| Bromide SCHEMBL3845240 | 0.76 | CTNNB1 (0.45) | KMT2ACTNNB1WNT3AALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | disclosed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | KMT2A 603/4885THRB 2955/4885CTNNB1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.